Cytokinetics, a South San Francisco-based biopharmaceutical company, develops muscle activators and inhibitors for diseases affecting muscle performance, with key drug candidates including aficamten and omecamtiv mecarbil. Founded in 2004, it employs 423 people and specializes in cardiac muscle function.
Muna Bhanji sold 1,454 shares of CYTK on 15 May at $29.73 per share, worth a total of $43K. They now own 23,510 CYTK shares, or a 6% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
